Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata
Depot microspheres of leuprorelin acetate provide efficacious, safe, and well-tolerated medical management for both endometriosis and uterine leiomyomata, overcoming the poor compliance associated with earlier GnRH agonist formulations.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (87)
- Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial via openalex
- A risk benefit assessment of drugs used in the treatment of endometriosis via openalex
- COMPARISON OF CELLULAR LEVELS OF STEROID RECEPTORS IN UTERINE LEIOMYOMA AND MYOMETRIUM via openalex
- Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results via openalex
- Hormonal effects of danazol and medical oophorectomy in endometriosis via openalex
- Hormonal therapies for endometriosis: implications for bone metabolism. via openalex
- Hormone treatment of endometriosis: the estrogen threshold hypothesis via openalex
- Leiomyomas: steroid receptor content. Variation within normal menstrual cycles via openalex
- Leuprolide acetate in the management of ureteral obstruction caused by endometriosis via openalex
- Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group via openalex
- Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone “add-back” therapy via openalex
- Reduced bone mass in reproductive-aged women with endometriosis via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist via openalex
- W1992601773 via openalex
- W1994190175 via openalex
- W1994281400 via openalex
- W1994965598 via openalex
- W1997894565 via openalex
- W1998169782 via openalex
- W1998413277 via openalex
- W1999450506 via openalex
- W2005679540 via openalex
- W2006732320 via openalex
- W2023138444 via openalex
- W2029700368 via openalex
- W2031495520 via openalex
- W2032629978 via openalex
- W2039795739 via openalex
- W2041129970 via openalex
- W2043018121 via openalex
- W2045157280 via openalex
- W2053593143 via openalex
- W2059516397 via openalex
- W2062729355 via openalex
- W2062982521 via openalex
- W2072114726 via openalex
- W2075125209 via openalex
- W2087874562 via openalex
- W2098019306 via openalex
- W2103818015 via openalex
- W2108806879 via openalex
- W2113298107 via openalex
- W2118357526 via openalex
- W2129449855 via openalex
- W2140086733 via openalex
- W2156149381 via openalex
- W2169489886 via openalex
- W2287757320 via openalex
- W2297593361 via openalex
- W2339861034 via openalex
- W2341127235 via openalex
- W2397913582 via openalex
- W2401502464 via openalex
- W2405398988 via openalex
- W2408995506 via openalex
- W2409900777 via openalex
- W2414394097 via openalex
- W2415257645 via openalex
- W2417044776 via openalex
- W2417748269 via openalex
- W2418911179 via openalex
- W2432841428 via openalex
- W2467395168 via openalex
- W4235473603 via openalex
- W4241190412 via openalex
- W4248449548 via openalex
- W4251799359 via openalex
- W4253023439 via openalex
- W4290264460 via openalex
- W6602169570 via openalex
- W6605565427 via openalex
- W6607058909 via openalex
- W6714082336 via openalex
- W6716996196 via openalex
- W6840958863 via openalex
- W54157561 via openalex
- W116555158 via openalex
- W168166682 via openalex
- W185315057 via openalex
- W223380701 via openalex
- W601549191 via openalex
- W1531102169 via openalex
- W1913675875 via openalex
- W1959742082 via openalex
- W1963501753 via openalex
- W1987244077 via openalex
- W1988605646 via openalex
Cited by (1)
SciLite annotations
chemicals 5
organisms 1
Source provenance
- europepmc
- last seen: 2026-10-12T06:17:10.165071+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T20:59:21.759586+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00